Back To: Home : Featured Technology : Reagents/Proteins

CLICK HERE FOR WHAT'S NEW IN:
 

Proteome Sciences licenses biomarker portfolio to Randox
May 2012
SHARING OPTIONS:

LONDON—Randox Laboratories has been granted a non-exclusive license by Proteome Sciences PLC to its portfolio of stroke biomarkers. Proteome Sciences' portfolio of patented plasma biomarkers for stroke and other brain damage-related disorders was discovered in partnership with the Biomedical Proteomics Research Group at the University of Geneva. That partnership demonstrated that a panel of five blood proteins can accurately rule out 90 percent of patients who have not had a stroke and may be misdiagnosed, and can confirm 90 percent of genuine strokes within minutes from the onset of symptoms. Per the agreement, Randox will develop products for the early diagnosis of stroke and monitoring of treatment outcomes. Though specific financial details were not provided, the agreement entitles Proteome Sciences to seven-digit license and development milestones and double-digit royalties on sales. 
 

Back


PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.